Original Article. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. Bhatt, M.D., Keith A.A. Fox, M.B., Ch.B. Dic - Ebook download as Text File (.txt), PDF File (.pdf) or read book online. Adlerian administer administrable administrate administratrix admiral admiralty admiration admire admissible admission admit admittance admitted admitting admix admixture admonish admonition ado adobe adolescent Adolph Adolphus Adonis. Adgrafix adgw adirondack adjusters adkins adlt admail admin administering administration administrations administrator admiral admit admn adobe adopt adopted. Berrys berryville berst bert berthold bertling bertolette bertram bertrand berwager berwick berwyn beso bessemer best bestweb beta betancourt betatest beth.

Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events Deepak L. Bhatt, M.D., Keith A.A. Fox, M.B., Ch.B., Werner Hacke, M.D., Peter B. Berger, M.D., Henry R.

Black, M.D., William E. Boden, M.D., Patrice Cacoub, M.D., Eric A. Cohen, M.D., Mark A. Creager, M.D., J.

Donald Easton, M.D., Marcus D. Flather, M.D., Steven M. Haffner, M.D., Christian W.

Hamm, M.D. Java Portable 64 Bit Download here. , Graeme J. Hankey, M.D., S. Claiborne Johnston, M.D., Koon-Hou Mak, M.D., Jean-Louis Mas, M.D., Gilles Montalescot, M.D., Ph.D., Thomas A. Pearson, M.D., P. Gabriel Steg, M.D., Steven R. Steinhubl, M.D., Michael A. Weber, M.D., Danielle M.

Brennan, M.S., Liz Fabry-Ribaudo, M.S.N., R.N., Joan Booth, R.N., and Eric J. Topol, M.D., for the CHARISMA Investigators N Engl J Med 2006; 354:1706-1717 DOI: 10.1056/NEJMoa060989. Results The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent and 17.9 percent (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P=0.04), and the rate of severe bleeding was 1.7 percent and 1.3 percent (relative risk, 1.25; 95 percent confidence interval, 0.97 to 1.61 percent; P=0.09). The rate of the primary end point among patients with multiple risk factors was 6.6 percent with clopidogrel and 5.5 percent with placebo (relative risk, 1.2; 95 percent confidence interval, 0.91 to 1.59; P=0.20) and the rate of death from cardiovascular causes also was higher with clopidogrel (3.9 percent vs. 2.2 percent, P=0.01).